Wegovy (Semaglutide) Guide To Uses, Dose, And Side Effects
Comprehensive guide to Wegovy: uses, dosage, side effects, and weight management for obesity and type 2 diabetes.
Wegovy is a brand name for semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist administered as a once-weekly subcutaneous injection. It is primarily indicated for weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or cardiovascular disease, in conjunction with reduced-calorie diet and increased physical activity. Semaglutide mimics the natural GLP-1 hormone, enhancing insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite to promote significant weight loss and better glycemic control.
What is Wegovy?
Wegovy contains semaglutide, a GLP-1 receptor agonist that acts similarly to the endogenous hormone GLP-1. This hormone is released in response to eating and helps regulate blood sugar by stimulating insulin release when glucose levels are high, while also promoting satiety and reducing food intake. Unlike short-acting GLP-1 agonists, semaglutide has a prolonged half-life, allowing for once-weekly dosing via pre-filled pens injected into the abdomen, thigh, or upper arm.
Originally developed for type 2 diabetes (as Ozempic), higher doses in Wegovy target obesity. Clinical trials demonstrate its efficacy: in one study of 1,961 adults, Wegovy users lost an average 15% body weight after 68 weeks versus 2% with placebo, with 84% achieving at least 5% loss. Another trial in 611 participants showed 16% average loss versus 6% placebo, bolstered by lifestyle counseling. For those with type 2 diabetes, a study of 1,210 adults reported 10% average loss versus 3% placebo.
Who can get it?
Wegovy is prescribed for adults meeting specific BMI criteria alongside diet and exercise. Eligibility includes:
- Adults with BMI ≥30 kg/m² (obesity).
- Adults with BMI ≥27 to <30 kg/m² (overweight) and at least one weight-related condition, such as prediabetes, type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.
It is not approved for type 1 diabetes, children under 18 (though studies in adolescents exist), or cosmetic weight loss without comorbidities. Patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should avoid it due to thyroid tumor risks in rodents. Consultation with a healthcare provider is essential to assess suitability.
How does Wegovy work?
Semaglutide binds to GLP-1 receptors, triggering multiple effects:
- Appetite regulation: Increases feelings of fullness, reduces hunger and cravings, leading to lower calorie intake.
- Glycemic control: Stimulates glucose-dependent insulin secretion and suppresses glucagon, lowering blood sugar in type 2 diabetes.
- Gastric effects: Slows stomach emptying, prolonging satiety.
- Cardiovascular benefits: Reduces risk of major adverse events like heart attack, stroke, or cardiovascular death in high-risk patients.
In the SELECT trial with over 17,600 participants, Wegovy reduced major cardiovascular events by 20% (6.5% vs. 8% placebo), alongside standard care. For kidney protection, it lowers risks of worsening chronic kidney disease in type 2 diabetes patients. Real-world data from Denmark (2022-2023) confirms its use in diverse patients for sustained weight management.
Dose
Wegovy dosing escalates gradually over 16-17 weeks to minimize gastrointestinal side effects:
| Week | Dose | Volume |
|---|---|---|
| 1-4 | 0.25 mg | 0.25 mL |
| 5-8 | 0.5 mg | 0.5 mL |
| 9-12 | 1 mg | 1 mL |
| 13-16 | 1.7 mg | 1.7 mL |
| 17+ | 2.4 mg (maintenance) | 2.4 mL |
Administer once weekly, same day each week, subcutaneously. If a dose is missed, take within 5 days; otherwise, skip and resume schedule. For type 2 diabetes variants (e.g., Ozempic), doses up to 2 mg weekly improve HbA1c by 0.18% more than 1 mg, though clinical meaningfulness is debated. Patients self-administer after training.
Possible side effects
Common side effects are gastrointestinal and dose-dependent, affecting up to 44% initially but decreasing over time:
- Very common (>1/10): Nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%), abdominal pain (20%), headache (14%), fatigue (11%), dyspepsia (9%), dizziness (8%), bloating (7%), belching (6%), hypoglycaemia in diabetics (6%), flatulence (6%), GERD (5%), fatigue (5%).
- Common (>1/100 to <1/10): Hypersensitivity, anxiety, insomnia, etc.
- Serious (rare): Acute pancreatitis, gallbladder disease, acute kidney injury, severe hypoglycemia with insulin/sulfonylureas, allergic reactions, thyroid tumors (black box warning), vision changes (diabetic retinopathy), suicidal thoughts.
Most resolve with time or dose adjustment. Cholecystitis risk increases with rapid weight loss. Monitor for dehydration from GI effects.
Who shouldn’t take Wegovy?
Contraindications include:
- Personal/family history of medullary thyroid carcinoma or MEN 2.
- Known semaglutide hypersensitivity.
- Pregnancy (Category C; discontinue 2 months prior) or breastfeeding (unknown if excreted in milk).
- Severe GI disease, e.g., gastroparesis.
Use caution in retinopathy, heart failure, or renal impairment. Not for underweight individuals or monotherapy without lifestyle changes.
Drug interactions
Wegovy delays gastric emptying, affecting oral medications:
- Insulin/sulfonylureas: Increased hypoglycemia risk; dose reductions needed.
- Oral contraceptives/hormonals: Reduced efficacy; use non-oral backup.
- Others: Monitor warfarin, digoxin, acetaminophen levels.
No major CYP interactions, but consult for polypharmacy.
Costs and funding
Wegovy is prescription-only, costs vary by region/insurance. In the UK, NHS funding possible via specialist services for eligible BMI/comorbidities. Privately, monthly pens ~£170-£250. US copays ~$0-£1000+ without coverage. Check local guidelines; not always funded for weight loss alone.
Where from?
Available via prescription from GPs, endocrinologists, or weight management clinics. Pre-filled pens from pharmacies. Global supply chain issues may affect availability; Novo Nordisk manages shortages.
More information
Patient leaflets detail storage (2-8°C, room temp up to 28 days). Clinical trials (STEP, SUSTAIN, SELECT) underpin approvals by EMA, FDA. Ongoing studies explore adolescent use, higher doses.
Frequently asked questions
Is Wegovy safe for long-term use?
Trials up to 2 years show sustained benefits with manageable side effects; long-term data ongoing. Cardiovascular safety confirmed.
How much weight can I lose?
Average 15-16% body weight in 68 weeks with lifestyle changes.
Does it cure diabetes?
No, manages type 2 diabetes; weight loss may improve control.
Can I drink alcohol on Wegovy?
Moderation advised; may exacerbate GI effects or hypoglycemia.
What if I miss a dose?
Take within 5 days; skip if longer, resume next week.
References
- Semaglutide (subcutaneous route) — Mayo Clinic. 2024. https://www.mayoclinic.org/drugs-supplements/semaglutide-subcutaneous-route/description/drg-20406730
- Wegovy — European Medicines Agency (EMA). 2024. https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy
- Semaglutide for Type 2 Diabetes (2 mg) — NCBI/NIH. 2024. https://www.ncbi.nlm.nih.gov/books/NBK598216/
- Semaglutide (Wegovy) — Cleveland Clinic. 2024. https://my.clevelandclinic.org/health/drugs/23611-semaglutide-injection-weight-management
- FDA Approves Wegovy for Heart Risk Reduction — U.S. FDA. 2024-03-06. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
- Semaglutide Injection — MedlinePlus/NIH. 2024. https://medlineplus.gov/druginfo/meds/a618008.html
- Real-World Use of Semaglutide for Weight Management — Diabetes Care (ADA). 2024. https://diabetesjournals.org/care/article/47/10/1834/157059/Real-World-Use-of-Semaglutide-for-Weight
Similar Articles
Read full bio of Sneha Tete
